(Q35009777)

5 August 2017

3 references

21 March 2019

2 October 2019

5 November 2020

Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review (English)

1 reference

Richard van Hillegersberg

5 August 2017

main subject

intestinal perforation

3 references

21 March 2019

2 October 2019

5 November 2020

1 reference

2 October 2019

angiogenesis inhibitor

1 reference

5 November 2020

4

object named as

R van Hillegersberg

1 reference

5 August 2017

Maudy Walraven

1

1 reference

5 August 2017

Petronella O Witteveen

2

1 reference

5 August 2017

Martijn P J Lolkema

3

1 reference

5 August 2017

Emile E Voest

5

1 reference

5 August 2017

H M W Verheul

6

1 reference

5 August 2017

publication date

29 December 2010

1 reference

5 August 2017

1 May 2011

3 references

21 March 2019

2 October 2019

5 November 2020

7

1 reference

inferred from page(s)

published in

Angiogenesis

4 references

5 August 2017

21 March 2019

2 October 2019

5 November 2020

14

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

135-141

1 reference

Creative Commons Attribution-NonCommercial 2.0 Generic

5 August 2017

copyright license

start time

29 December 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10456-010-9197-6

0 references

cites work

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Gastrointestinal perforation due to bevacizumab in colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Cellular and molecular mechanisms of gastrointestinal ulcer healing

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Vascular endothelial growth factor: basic science and clinical progress

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Fundamental Concepts of the Angiogenic Process

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Platelet: transporter of vascular endothelial growth factor

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

What Is the Evidence That Tumors Are Angiogenesis Dependent?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma

8 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-010-9197-6

Bowel perforation after radiotherapy in a patient receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-010-9197-6

Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-010-9197-6

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-010-9197-6

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-010-9197-6

Identification of functional VEGF receptors on human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-010-9197-6

Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Dynamics of changes in vascular endothelial growth factor (VEGF) expression and angiogenesis in stress-induced gastric ulceration in rats

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

A possible defensive mechanism in the basal region of gastric mucosa and the healing of erosions

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102838

Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells

26 October 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-010-9197-6

Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation

21 January 2018

1 reference

12 December 2020

Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?

1 reference

12 December 2020

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

12 December 2020

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

12 December 2020

Platelets Take Up the Monoclonal Antibody Bevacizumab

1 reference

12 December 2020

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening

1 reference

12 December 2020

10.1007/S10456-010-9197-6

Identifiers

DOI

1 reference

5 August 2017

1 reference

5 August 2017

1 reference